Preparation method of citalopram impurity

Preparation of citalopram impurities through oxidation and reduction reactions has solved the problem of unstable and efficient preparation of citalopram impurities in the prior art, achieved high yield and high purity preparation, and provided qualitative and quantitative for the synthesis of raw materials for the raw materials. The basis for analysis has improved the quality of the drug.

CN119080725APending Publication Date: 2024-12-06CHINA NAT PHARM IND CORP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411120677.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to prepare citalopram impurities stably and efficiently, which affects the quality of drugs and the qualitative and quantitative analysis of the synthesis process of raw materials.

Method used

Preparation by oxidation of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile in free state with Jones reagent Citalopram impurity C was obtained and a reduction reaction with DIBAL-H was performed on the raw material to obtain Citalopram impurity B, and the reaction conditions such as molar ratio, solvent selection, temperature and time were controlled.

Benefits of technology

The stable and high yield preparation of citalopram impurities is achieved, high-purity reference products are provided, and the qualitative and quantitative analysis capabilities of drug quality are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004994989060000031
    Figure BDA0004994989060000031
Patent Text Reader

Abstract

The invention relates to a preparation method of a citalopram impurity. The preparation method comprises the following steps: oxidizing free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethyl cyanophenyl hydrobromide and a Jones reagent to prepare the citalopram impurity C; the citalopram impurity C is used as a raw material, the citalopram impurity C and DIBAL-H are subjected to a reduction reaction to prepare a citalopram impurity B, and the citalopram impurity B is 1-(3-(dimethylamino) propyl)-1-(4-fluorophenyl)-3-hydroxy-1, 3-dihydro-5-nitrile isobenzofuran. Therefore, the citalopram impurity can be stably obtained with high yield, and a basis is provided for qualitative and quantitative impurity in a raw material medicine synthesis process.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug synthesis, and in particular to a method for preparing a citalopram impurity. Background Art

[0002] Citalopram, chemical name: 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile, is a widely used selective serotonin reuptake inhibitor antidepressant (SSRIs). Since its launch in Denmark in 1989, it has been quickly recommended as the first choice for the treatment of depression due to its strong effect, good tolerance and few side effects. Impurities in drugs are an important factor affecting drug quality. The study of drug impurities is of great significance in the research and development of raw material technology, research and development of preparation technology, and the investigation of drug stability and bioequivalence.

[0003] Therefore, a method for preparing citalopram impurities is provided so as to obtain citalopram impurities stably and in high yield, thereby providing a basis for the qualitative and quantitative characterization of impurities in the raw material drug synthesis process, which is of great significance to the development of the synthesis process of citalopram raw material drug and is a problem to be solved urgently by those skilled in the art. Summary of the invention

[0004] In view of the defects in the prior art, the object of the present invention is to provide a method for preparing citalopram impurities so as to obtain citalopram impurities stably and in high yield, thereby providing a basis for the qualitative and quantitative determination of impurities in the synthesis process of raw materials.

[0005] To achieve the above purpose, the technical solution provided by the present invention is:

[0006] A method for preparing a Citalopram impurity comprises the following steps:

[0007] The free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile hydrobromide was oxidized with Jones reagent to obtain Citalopram impurity C;

[0008] Citalopram impurity C is used as a raw material to undergo a reduction reaction with DIBAL-H to obtain Citalopram impurity B, wherein the Citalopram impurity B is 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-5-nitrile isobenzofuran.

[0009] Optionally, when preparing Citalopram impurity C, the molar ratio of free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile to chromium trioxide in Jones reagent is 1:1 to 1:1.5.

[0010] Optionally, when preparing Citalopram impurity C, the solvent used in the reaction is one of sulfuric acid, acetone, water or dichloromethane.

[0011] Optionally, when preparing Citalopram impurity C, the volume ratio of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile used in the reaction to the solvent is 1:3 to 1:20.

[0012] Optionally, when preparing Citalopram impurity C, the reaction temperature is -15°C to 0°C, and the reaction time is 0.5 to 3 hours.

[0013] Optionally, when preparing Citalopram impurity B, the molar ratio of Citalopram impurity C to DIBAL-H is 1:2 to 1:4.

[0014] Optionally, when preparing Citalopram impurity B, the solvent used in the reaction is one of toluene, tetrahydrofuran, water, acetone or 15% NaOH.

[0015] Optionally, when preparing Citalopram impurity B, the relationship between the volume of quenching solvent water and DIBAL-H used in the first reaction is V 水 =0.04*1.2*V DIBAL-H ;

[0016] The relationship between the volume of quenching solvent water and DIBAL-H used in the second reaction is V 水 =0.1*1.2*V DIBAL-H ;

[0017] The relationship between the volume of quenching solvent 15% NaOH and DIBAL-H used in the reaction is V NaOH =0.04*1.2*V DIBAL-H .

[0018] Optionally, when preparing Citalopram impurity B, the quenching solvent sequence is: water, 15% NaOH, water, and the reaction temperature is maintained below 5°C.

[0019] Optionally, when preparing Citalopram impurity B, the reaction temperature is -80°C to -70°C, and the reaction time is 10 to 40 min.

[0020] The technical solution provided by the present invention has the following beneficial effects: the present invention creatively provides a method for preparing citalopram impurities, which can obtain citalopram impurities stably and in high yield, thereby providing a basis for the qualitative and quantitative analysis of impurities in the raw material drug synthesis process; its effective preparation and investigation provide sufficient and qualified reference substances for the qualitative and quantitative analysis of the impurity levels in the drug escitalopram oxalate, which is of great significance to improving the quality of drugs.

[0021] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. DETAILED DESCRIPTION

[0022] The technical scheme of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. The following examples are only used to more clearly illustrate the technical scheme of the present invention, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional reagent stores unless otherwise specified. The quantitative tests in the following examples are all set for three replicates, and the data are the mean values ​​or mean values ​​± standard deviations of the three replicates.

[0023] The invention discloses a preparation method of a citalopram impurity B: 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-5-nitrile isobenzofuran, and provides a basis for the qualitative and quantitative analysis of impurities in a raw material drug synthesis process.

[0024] Among them, the reaction formula is as follows:

[0025]

[0026] In a specific embodiment, the method for preparing the citalopram impurity provided by the present invention comprises the following steps:

[0027] S1: Free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile hydrobromide was oxidized with Jones reagent to obtain Citalopram impurity C;

[0028] S2: Using Citalopram impurity C as a raw material to undergo a reduction reaction with DIBAL-H to obtain Citalopram impurity B, wherein the Citalopram impurity B is 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-5-nitrileisobenzofuran.

[0029] Wherein, in step S1, when preparing citalopram impurity C, the molar ratio of free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile to chromium trioxide in Jones reagent is 1:1 to 1:1.5, preferably 1:1.3.

[0030] When preparing Citalopram impurity C, the solvent used in the reaction is one of sulfuric acid, acetone, water or dichloromethane, the volume ratio of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile used in the reaction to the solvent is 1:3 to 1:20, the reaction temperature is -15°C to 0°C, and the reaction time is 0.5 to 3h.

[0031] That is to say, the solvent used for the reaction in the preparation method of impurity C is selected from: sulfuric acid, acetone, water, and dichloromethane, wherein sulfuric acid is mixed with chromium trioxide to form Jones reagent, wherein the amount of sulfuric acid is 4 times the amount of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile, the volume of acetone is 20 times the amount of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile, and the volume of water is 3 times the amount of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile.

[0032] In the above specific embodiment, when the method prepares the citalopram impurity B, the molar ratio of the citalopram impurity C to DIBAL-H is 1:2 to 1:4, preferably 1:3.5, and can be added in batches. The solvent used in the reaction is one of toluene, tetrahydrofuran, water, acetone or 15% NaOH, and the relationship between the volume of the quenching solvent water and DIBAL-H used in the first reaction is V 水 =0.04*1.2*V DIBAL-H The relationship between the volume of quenching solvent water and DIBAL-H used in the second reaction is V 水 =0.1*1.2*V DIBAL-H The relationship between the volume of the quenching solvent 15% NaOH and DIBAL-H used in the reaction is V NaOH =0.04*1.2*V DIBAL-H The order of quenching solvents is: water, 15% NaOH, water, and the reaction temperature is maintained below 5°C, the reaction temperature is -80°C to -70°C, and the reaction time is 10 to 40 minutes.

[0033] The technical solution provided by the present invention is further described below in conjunction with specific embodiments.

[0034] Example

[0035] The raw materials and reagents involved in the present invention are all commercially available.

[0036] At 80°C, 7 g of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile hydrobromide was dissolved in purified water, the pH was adjusted to about 11 with 40% NaOH, and the mixture was washed with dichloromethane and saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated to obtain 5.4 g of free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile.

[0037] At room temperature, 5 g of free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile was dissolved in 50 mL of acetone, cooled to -5°C, and Jones reagent (2.7 g CrO3 dissolved in 8.3 mL H2SO4 / H2O) was slowly added dropwise. After the addition was complete, stirring was continued, and the reaction was monitored by TLC (dichloromethane: methanol = 5:1). At -5°C, 100 mL of purified water was added to the reaction solution, and the pH was adjusted to about 11 with 40% NaOH to produce a large amount of inorganic salts. The mixture was filtered off with diatomaceous earth, and the filter cake was washed with purified water and dichloromethane. The filtrate was extracted with dichloromethane three times, and the organic phase was washed with purified water twice. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated under reduced pressure to obtain 3.6 g of impurity C as an oily substance. The yield was 71.5%, and the purity was 96.33% (HPLC area normalization method).

[0038] Under nitrogen environment, put 4g impurity C into a 250mL three-necked flask, add 40mL anhydrous tetrahydrofuran, cool liquid nitrogen to -70℃, add 40mL DIBAL-H dropwise with a syringe, keep warm for 20min, and monitor the reaction by TLC. After the reaction is completed, slowly heat up to -30℃, add 1.87mL water, 1.87mL 15% sodium hydroxide, and then add 4.68mL water to quench the reaction solution, slowly heat up to 15℃, add anhydrous sodium sulfate to dry, filter, distill the filtrate under reduced pressure, pass through a silica gel column (CH2Cl2:CH3OH=10:1), collect the product spots, and rotary evaporate to obtain 1.2g of oily liquid, yield: 30%, purity: 98.53% (HPLC area normalization method).

[0039] It can be seen from the above embodiments that the present invention creatively provides a method for preparing citalopram impurities, which can obtain citalopram impurities stably and in high yield, and the prepared impurities have high purity, thereby providing a basis for the qualitative and quantitative analysis of impurities in the raw material synthesis process. Its effective preparation and investigation provide sufficient and qualified reference substances for the qualitative and quantitative analysis of the impurity levels in the drug escitalopram oxalate, which is of great significance to improving the quality of drugs.

[0040] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should be the usual meanings understood by those skilled in the art to which the present invention belongs. Unless otherwise specified, the relative steps, numerical expressions and numerical values ​​of the parts and steps set forth in these embodiments do not limit the scope of the present invention. In all examples shown and described here, unless otherwise specified, any specific value should be interpreted as being merely exemplary, rather than as a limitation, and therefore, other examples of exemplary embodiments may have different values.

[0041] In the description of the present invention, it should be understood that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is more than two, unless otherwise clearly and specifically defined.

[0042] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the protection scope of the present invention.

Claims

1. A method for preparing a Citalopram impurity, characterized in that: The following steps are involved: The free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile hydrobromide was oxidized with Jones reagent to obtain Citalopram impurity C; Citalopram impurity C is used as a raw material to undergo a reduction reaction with DIBAL-H to obtain Citalopram impurity B, wherein the Citalopram impurity B is 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-5-nitrile isobenzofuran.

2. The method for preparing Citalopram impurities according to claim 1, characterized in that: When preparing Citalopram impurity C, the molar ratio of free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile to chromium trioxide in Jones reagent is 1:1 to 1:1.

5.

3. The method for preparing Citalopram impurities according to claim 1, characterized in that: When preparing Citalopram impurity C, the solvent used in the reaction is one of sulfuric acid, acetone, water or dichloromethane.

4. The method for preparing Citalopram impurities according to claim 3, characterized in that: When preparing Citalopram impurity C, the volume ratio of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethylbenzonitrile used in the reaction to the solvent is 1:3 to 1:

20.

5. The method for preparing Citalopram impurities according to claim 1, characterized in that: When preparing Citalopram impurity C, the reaction temperature is -15°C to 0°C, and the reaction time is 0.5 to 3 hours.

6. The method for preparing the Citalopram impurity according to any one of claims 1 to 5, characterized in that: When preparing Citalopram impurity B, the molar ratio of Citalopram impurity C to DIBAL-H is 1:2 to 1:

4.

7. The method for preparing Citalopram impurities according to claim 6, characterized in that: When preparing Citalopram impurity B, the reaction solvent used is one of toluene, tetrahydrofuran, water, acetone or 15% NaOH.

8. The method for preparing Citalopram impurities according to claim 7, characterized in that: When preparing Citalopram impurity B, the relationship between the volume of quenching solvent water and DIBAL-H used in the first reaction is V 水 =0.04*1.2*V DIBAL-H ; The relationship between the volume of quenching solvent water and DIBAL-H used in the second reaction is V 水 =0.1*1.2*V DIBAL-H ; The relationship between the volume of quenching solvent 15% NaOH and DIBAL-H used in the reaction is V NaOH =0.04*1.2*V DIBAL-H .

9. The method for preparing Citalopram impurities according to claim 8, characterized in that: When preparing Citalopram impurity B, the quenching solvent sequence is: water, 15% NaOH, water, and the reaction temperature is maintained below 5°C.

10. The method for preparing Citalopram impurities according to claim 9, characterized in that: When preparing Citalopram impurity B, the reaction temperature is -80°C to -70°C, and the reaction time is 10 to 40 minutes.